FrancophonIA/ELRC3.0 huggingface dataset:
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/022 [10 prolonged-release tablets] EU/1/97/050/023 [30 prolonged-release tablets] EU/1/97/050/024 [100 prolonged-release tablets]
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/97/050/022 [10 tableta s produljenim oslobađanjem] EU/1/97/050/023 [30 tableta s produljenim oslobađanjem] EU/1/97/050/024 [100 tableta s produljenim oslobađanjem]
English: INFORMATION IN BRAILLE SIFROL 2.1 mg prolonged-release tablets 17.
Croatian: 16. PODACI NA BRAILLEOVOM PISMU SIFROL 2,1 mg tablete s produljenim oslobađanjem
English: The tablets are white, flat, of oval shape, scored on both sides, and have a code embossed (one side with the code P8, and one side with the Boehringer Ingelheim company symbol).
Croatian: Tablete su bijele, plosnate, ovalnog oblika, s razdjelnim urezom na obje strane te imaju otisnutu oznaku (s jedne strane oznaku P8, a s druge strane simbol tvrtke Boehringer Ingelheim).
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/019 [10 prolonged-release tablets] EU/1/97/050/020 [30 prolonged-release tablets] EU/1/97/050/021 [100 prolonged-release tablets]
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/97/050/019 [10 tableta s produljenim oslobađanjem] EU/1/97/050/020 [30 tableta s produljenim oslobađanjem] EU/1/97/050/021 [100 tableta s produljenim oslobađanjem]
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/005 [30 tablets]
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/97/050/005 [30 tableta]
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/001 [30 tablets]
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/97/050/001 [30 tableta]
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/050/003 [30 tablets]
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/97/050/003 [30 tableta]
English: 1 tablet SIFROL 0.18 mg OR
Croatian: Broj tableta 1 tableta SIFROL 0,18 mg
English: One SIFROL 0.52 mg prolonged-release tablet, OR two SIFROL 0.26 mg prolonged-release tablets.
Croatian: SIFROL 0,52 mg tablete s produljenim oslobađanjem Jedna tableta s produljenim oslobađanjem sadrži 0,75 mg pramipeksoldiklorid hidrata, što odgovara 0,52 mg pramipeksola.
English: 2 tablets SIFROL 0.088 mg
Croatian: 2 tablete SIFROL 0,088
English: NAME OF THE MEDICINAL PRODUCT SIFROL 2.62 mg prolonged-release tablets Pramipexole
Croatian: SIFROL 2,62 mg tablete s produljenim oslobađanjem pramipeksol
English: Ciambra is a ‘generic medicine'.
Croatian: Ciambra je „generički lijek”.
English: The full EPAR and risk management plan summary for Ciambra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Ciambra nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This means that Ciambra is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
Croatian: To znači da je Ciambra sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Alimta.
English: Ciambra is a cancer medicine used to treat two types of lung cancer:
Croatian: Ciambra je lijek protiv raka koji se primjenjuje u liječenju dva tipa raka pluća:
English: Because Ciambra is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Ciambra generički lijek, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: Other information about Ciambra
Croatian: Ostale informacije o lijeku Ciambra
English: What measures are being taken to ensure the safe and effective use of Ciambra?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Ciambra?
English: It is not intended to provide practical advice on how to use Ciambra.
Croatian: Svrha sažetka nije davati praktične savjete o načinu primjene lijeka Ciambra.
English: What is Ciambra and what is it used for?
Croatian: Što je Ciambra i za što se koristi?
English: What are the benefits and risks of Ciambra?
Croatian: Koje su koristi i rizici lijeka Ciambra?
English: This is a summary of the European public assessment report (EPAR) for Ciambra.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Ciambra.
English: A risk management plan has been developed to ensure that Ciambra is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Ciambra.
English: Why is Ciambra approved?
Croatian: Zašto je Ciambra odobren?
English: Ciambra is available as a powder that is made up into a solution for infusion (drip) into a vein.
Croatian: Ciambra je dostupan kao prašak koji se koristi za pripremu otopine za infuziju (drip) u venu.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ciambra, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Ciambra nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ciambra has been shown to be comparable to Alimta.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je kako je u skladu sa zahjevima EUa dokazano da je lijek Ciambra usporediv s lijekom Alimta.
English: No additional studies were needed as Ciambra is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Croatian: Nisu bila potrebna dodatna ispitivanja jer je Ciambra generički lijek koji se daje infuzijom i sadrži istu djelatnu tvar kao i referentni lijek Alimta.
English: The Committee recommended that Ciambra be approved for use in the EU.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Ciambra u EU-u.
English: For more information about treatment with Ciambra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Ciambra pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: When Ciambra is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Croatian: Ako se Ciambra primjenjuje s cisplatinom, prije ili nakon doze cisplatina bolesniku također treba dati „antiemetik” (za sprječavanje povraćanja) i tekućinu (za sprječavanje dehidracije).
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Ciambra.
Croatian: Kako bi se ublažile nuspojave lijeka, bolesnici tijekom terapije lijekom Ciambra trebaju uzimati kortikosteroid (tip lijeka koji smanjuje upalu) i folnu kiselinu (tip vitamina) te primati injekcije vitamina B12.
English: For practical information about using Ciambra, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Ciambra pročitajte u uputi o lijeku ili se obratite svom liječniku ili ljekarniku.
English: The active substance in Ciambra, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'.
Croatian: Djelatna tvar lijeka Ciambra, pemetreksed, citotoksičan je lijek (lijek koji uzrokuje smrt stanica koje se dijele, kao što su stanice karcinoma), a ubraja se u grupu „antimetabolita”.
English: How does Ciambra work?
Croatian: Kako djeluje Ciambra?
English: Ciambra pemetrexed
Croatian: Ciambra pemetreksed
English: How is Ciambra used?
Croatian: Kako se Ciambra koristi?
English: Ciambra contains the active substance pemetrexed.
Croatian: Sadrži djelatnu tvar pemetreksed.
English: How has Ciambra been studied?
Croatian: Kako je Ciambra ispitivan?
English: EU/1/15/989/001
Croatian: EU/1/15/989/001 Orbactiv
English: 400 mg Powder for concentrate for solution for infusion
Croatian: 400 mg Prašak za koncentrat za otopinu za infuziju
English: Intravenous use vial (glass)
Croatian: Za primjenu u venu staklenoj bočici
English: Movymia teriparatide
Croatian: Movymia teriparatid
English: The full EPAR for Movymia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Movymia nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: • men who are at an increased risk of fractures;
Croatian: • muškaraca s povećanim rizikom od prijeloma;
English: Movymia must not be used during pregnancy or breastfeeding.
Croatian: Lijek Movymia ne smije se koristiti tijekom trudnoće ili dojenja.
English: This means that Movymia is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Croatian: Drugim riječima, Movymia je sličan biološkom lijeku (poznatom kao „referentni lijek”) koji je već odobren u Europskoj uniji (EU).
English: This was considered sufficient to conclude that Movymia will behave in the same way in terms of effectiveness and safety.
Croatian: To se smatralo dostatnim za donošenje zaključka da će se lijek Movymia ponašati na isti način u pogledu djelotvornosti i sigurnosti.
English: The most common side effect with Movymia (seen in more than 1 patient in 10) is pain in the arms or legs.
Croatian: Najčešća nuspojava lijeka Movymia (uočena u više od 1 na 10 osoba) je bol u rukama ili nogama.
English: What measures are being taken to ensure the safe and effective use of Movymia?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Movymia?
English: What is Movymia and what is it used for?
Croatian: Što je Movymia i za što se koristi?
English: Thus, as for Forsteo, the benefit outweighs the identified risks and the Committee recommended that Movymia be given marketing authorisation.
Croatian: Stoga, kao i kod lijeka Forsteo, korist nadmašuje identificirane rizike te je Odbor preporučio davanje odobrenja za stavljanje lijeka Movymia u promet.
English: Movymia is a ‘biosimilar medicine'.
Croatian: Movymia je „biosličan lijek”.
English: This is a summary of the European public assessment report (EPAR) for Movymia.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Movymia.
English: A study in 54 healthy women has shown that the same doses of the two medicines given by injection under the skin produced similar levels of the active substance teriparatide in the body.
Croatian: Ispitivanje koje je uključivalo 54 zdrave žene pokazalo je da su jednake doze tih dvaju lijekova primijenjenih injekcijom pod kožu proizvele slične razine djelatne tvari teriparatida u tijelu.
English: Because Movymia is a biosimilar medicine, the studies on effectiveness and safety of teriparatide carried out with Forsteo do not need to be repeated for Movymia.
Croatian: Budući da je lijek Movymia biosličan lijek, ispitivanja djelotvornosti i sigurnosti teriparatida provedena za lijek Forsteo nije potrebno ponavljati za lijek Movymia.
English: Movymia is a medicine used for the treatment of osteoporosis (a disease that makes bones fragile) in:
Croatian: Movymia je lijek koji se primjenjuje u liječenju osteoporoze (bolesti koja kosti čini krhkima) u:
English: Movymia must not be used in patients who have other bone diseases such as Paget's disease, bone cancer or bone metastases (cancer that has spread to the bone), patients who have had radiation therapy of the skeleton, or patients who have hypercalcaemia (high blood calcium levels), unexplained high levels of alkaline phosphatase (an enzyme) or severe kidney disease.
Croatian: Lijek Movymia ne smije se primjenjivati u bolesnika koji boluju od drugih bolesti kostiju kao što je Pagetova bolest, rak kostiju ili metastaze u kostima (rak koji se proširio na kosti), u bolesnika koji su liječeni zračenjem kostiju ili u bolesnika koji boluju od hiperkalcemije (visoka razina kalcija u krvi), u bolesnika s neobjašnjeno visokim razinama alkalne fosfataze (enzim) ili teškom bolesti bubrega.
English: It also increases the absorption of calcium from food and prevents too much calcium being lost in the urine.
Croatian: Također povećava apsorpciju kalcija iz hrane te sprječava preveliko izlučivanje kalcija urinom.
English: Movymia is available as a solution for injection in cartridges (containing 600 micrograms of teriparatide) intended to be used with ServoPen Fix system.
Croatian: Lijek Movymia dostupan je kao otopina za injekciju u ulošcima (koji sadržavaju 600 mikrograma teriparatida) namijenjenima za uporabu sa sustavom ServoPen Fix.
English: What are the risks associated with Movymia?
Croatian: Koji su rizici povezani s lijekom Movymia?
English: It is not intended to provide practical advice on how to use Movymia.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Movymia.
English: It acts like the hormone to stimulate bone formation by acting on osteoblasts (bone-forming cells).
Croatian: Djeluje kao hormon kako bi se stimuliralo stvaranje kostiju djelujući na osteoblaste (stanice koje stvaraju kost).
English: In women, osteoporosis is more common after the menopause, when the levels of the female hormone oestrogen fall.
Croatian: U žena je osteoporoza učestalija nakon menopauze, nakon što se razine ženskog hormona estrogena smanje.
English: Osteoporosis can also occur as a side effect of glucocorticoid treatment in men and women.
Croatian: Osteoporoza može također nastupiti kao nuspojava terapije glukokotikoidom u muškaraca i žena.
English: • men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid).
Croatian: • muškaraca i žena s povećanim rizikom od prijeloma zbog dugotrajne terapije glukokortikoidima
English: Other information about Movymia
Croatian: Ostale informacije o lijeku Movymia
English: The reference medicine for Movymia is Forsteo.
Croatian: Referentni lijek za Movymia je Forsteo.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) considered evidence showing that Movymia has a highly similar structure, purity and biological activity to Forsteo and is distributed in the body in the same way.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji razmotrio je dokaze koji pokazuju da lijek Movymia ima vrlo sličnu strukturu i biološku aktivnosti kao i lijek Forsteo i istu distribuciju u tijelu.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Movymia have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Movymia nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 mikrograma lijeka Movymia jednom na dan injekcijom ispod kože bedra ili abdomena (trbuha).
English: Why is Movymia approved?
Croatian: Zašto je lijek Movymia odobren?
English: For more information about treatment with Movymia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Movymia pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: The active substance in Movymia, teriparatide, is identical to part of the human parathyroid hormone.
Croatian: Djelatna tvar lijeka Movymia, teriparatid, identična je dijelu humanog paratiroidnog hormona.
English: For practical information about using Movymia, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Movymia bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: Further, Movymia and Forsteo produced similar effects on calcium levels in the blood.
Croatian: Nadalje, lijek Movymia uzrokovao je slične učinke na razinu kalcija u krvi kao i lijek Forsteo.
English: How does Movymia work?
Croatian: Kako djeluje Movymia?
English: Gradually, the bones become less dense and more likely to break.
Croatian: Gustoća kostiju postupno se smanjuje i kosti postaju podložnije lomovima.
English: What benefits of Movymia have been shown in studies?
Croatian: Koje su koristi lijeka Movymia dokazane u ispitivanjima?
English: How is Movymia used?
Croatian: Kako se Movymia koristi?
English: Laboratory studies comparing Movymia with Forsteo have shown that the active substance in Movymia is highly similar to that in Forsteo in terms of structure, purity and biological activity.
Croatian: Laboratorijska ispitivanja u kojima je lijek Movymia uspoređen s lijekom Forsteo pokazala su da postoji velika sličnost između djelatne tvari lijeka Movymia i djelatne tvari lijeka Forsteo u pogledu strukture, čistoće i biološke aktivnosti.
English: • women who have been through the menopause.
Croatian: • žena u postmenopauzi.
English: For the full list of all side effects reported with Movymia, see the package leaflet.
Croatian: Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Movymia potražite u uputi o lijeku.
English: Patients may inject themselves once they have been trained.
Croatian: Ako prođu odgovarajuću obuku, bolesnici si mogu samostalno injicirati lijek.
English: Movymia contains the active substance teriparatide.
Croatian: Lijek Movymia sadrži djelatnu tvar teriparatid.
English: In these patients, Movymia has been shown to significantly reduce vertebral (spine) and non-vertebral fractures (broken bones), but not those of the hip;
Croatian: (spinalne) i nevertebralne prijelome (slomljene kosti), no ne i prijelom kuka;
English: The two-year course of Movymia should be given only once during a patient's lifetime.
Croatian: Tijekom života bolesnik ne smije primiti više od jednog dvogodišnjeg ciklusa liječenja lijekom Movymia.
English: Patients should receive calcium and vitamin D supplements if they do not get enough from their diet. Movymia can be used for up to two years.
Croatian: Bolesnici trebaju primati nadomjeske kalcija i vitamina
English: CMDh position
Croatian: Mišljenje CMDh-a
English: The product information was amended accordingly.
Croatian: Informacije o proizvodu su prema tome dopunjene.
English: Grounds for the PRAC recommendation
Croatian: Razlozi za preporuku PRAC-a
English: However, on a population level, the randomised trials only showed convincing evidence of efficacy of the 10mg dose of zolpidem.
Croatian: No, na razini populacije, randomizirana ispitivanja su pokazala samo uvjerljivi dokaz o djelotvornosti doze od 10 mg zolpidema.
English: Scientific conclusions and grounds for the variation to the terms of the marketing authorisations
Croatian: Znanstveni zaključci i razlozi za izmjenu uvjeta odobrenja za stavljanje lijeka u promet
English: The currently recommended daily dose in the elderly and in patients with hepatic impairment is 5mg, and this dose recommendation remains unchanged in the product information.
Croatian: Trenutno preporučena dnevna doza u starijih osoba i u bolesnika s oštećenjem jetre iznosi 5 mg, te preporuka za ovu dozu ostaje nepromijenjena u informacijama o proizvodu.
English: The PRAC therefore agreed that the recommended daily dose of zolpidem should not be reduced for adults.
Croatian: Stoga je PRAC suglasan da se preporučena dnevna doza zolpidema ne treba smanjiti za potrebe odraslih osoba.
English: It was however acknowledged that in some patients a lower dose of 5mg could be effective.
Croatian: No, potvrdio je da manja doza od 5 mg može biti djelotvorna u pojedinih bolesnika.
English: Therefore in July 2013, AIFA requested the PRAC to give a recommendation under Article 31 of Directive 2001/83/EC on whether marketing authorisation of these products should be maintained, varied, suspended, or withdrawn.
Croatian: Stoga u srpnju 2013. godine, AIFA je zatražila preporuku PRAC-a sukladno članku 13. Direktive 2001/83/EZ o tome treba li se odobrenja za stavljanje lijeka u promet za ove proizvode održati, izmijeniti, suspendirati ili povući.
English: Based on evidence from the literature, it was considered necessary to amend and harmonise the ‘Interaction with other medicinal products' section of the product information.
Croatian: Na temelju dokaza iz literature, smatra se da je potrebno dopuniti i uskladiti poglavlja „interakcija s drugim lijekovima” u informacijama o lijeku.
English: Overall summary of the scientific evaluation by PRAC
Croatian: Cjelokupan sažetak znanstvene ocjene PRAC-a
English: The analysis of the submitted individual case reports of driving ability and somnambulism showed that whatever the age and gender category, most of the cases of impaired driving were reported at a 10mg daily dose for both events.
Croatian: Analiza dostavljenih izvješća individualnih slučajeva smanjene sposobnosti upravljanja vozilom i somnambulizma pokazala je da bez obzira na kategoriju dobi i spola, većina slučajeva smanjenje sposobnosti upravljanja vozilom prijavljena je za dnevnu dozu od 10 mg za oba slučaja.
English: • The PRAC considered the procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data for zolpidem-containing medicinal products;
Croatian: • je PRAC razmotrio postupak proveden sukladno članku 31. Direktive 2001/83/EZ koji rezultira iz farmakovigilancijskih podataka za lijekove koji sadrže zolpidem;
English: It was therefore considered by the PRAC that the dosing recommendation should include instructions that Zolpidem is to be taken in a single intake immediately at bedtime and should not be re-administered during the same night.
Croatian: Stoga je PRAC zaključio da preporuka o doziranju mora uključivati upute da se Zolpidem treba uzimati u jednom unosu neposredno prije odlaska na počinak te da se ne smije uzimati ponovno tijekom noći.
English: In February 2013, the Pharmacovigilance Risk Assessment Committee (PRAC) discussed the results of the search in EudraVigilance (EV) of cases of impaired driving ability as well as road traffic accidents associated with zolpidem, performed by the Italian Competent Authority (AIFA).
Croatian: U veljači 2013. godine, Povjerenstvo za ocjenu rizika na području farmakovigilancije (PRAC) raspravio je rezultate istraživanja sadržanog u EudraVigilance (EV) sustavu slučajeva smanjenje sposobnosti upravljanja vozilima kao i prometnih nesreća povezanih sa zolpidemom, koje je provelo nadležno tijelo u Italiji (AIFA).
English: Finally and in view of further minimising the risks of impaired driving and somnambulism, a potential lowering of the recommended dose for adults was discussed by the PRAC.
Croatian: Zaključno i sa ciljem daljnjeg smanjivanja rizika od oslabljene sposobnosti upravljanja vozilom i somnambulizma, PRAC je razmotrio potencijalno snižavanje preporučene doze za odrasle osobe.
English: • The PRAC also reviewed the available data on the efficacy of zolpidem in order to determine whether amendments to the posology would help to minimise the risks but agreed that the available efficacy data do not provide robust evidence that a lower dose would be effective on a population level;
Croatian: • je PRAC također pregledao podatke dostupne o djelotvornosti zolpidema kako bi utvrdio da li bi dopune o doziranju pomogle u smanjivanju rizika, no složio se da dostupni podaci o učinkovitosti ne pružaju čvrsti dokaz da bi manja doza bila učinkovitija na razini populacije;